Alcon is paying ThromboGenics €75 million to take over commercialization of ocriplasmin in all markets outside the U.S. ThromboGenics has completed a clinical development program that included two successful Phase III studies that have shown that ocriplasmin could play an important role in treating symptomatic vitreomacular adhesion (VMA) including macular hole.
Thrombogenics is also entitled to a €90 million in near-term milestone payments, future milestones of €210 million, and royalties. The company will concentrate on commercializing ocriplasmin in the U.S. where it plans to build its commercial and medical organization to support the product’s anticipated launch within the next 12 months.
Under the agreement, ThromboGenics will still have a strategic and focused operational role in the commercialization of ocriplasmin in the five largest European markets, enabling it to build the foundation for an expanding ophthalmology franchise. In addition to the commercial introduction of ocriplasmin in markets outside the U.S., the agreement specifies that Alcon and ThromboGenics will work together and share the costs to further develop new clinical applications of the product that the companies will introduce in their respective territories.